BB's Stock Haven

[dirkv]

Jagx: 0.06
52 Week Range 0.0510 - 2.3000

https://jaguar.health/pipeline/

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173911094
Product revenue more than 10 million for 2023
Total assets $ 45,380,000
millions shares are short.
Free float of less than $2,500,000
Iliad Research & Trading LP : 4,875,000
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9.6 %
Based on the 50,755,580 shares outstanding
Time for a very strong rebound:

Feb 23, 2024 0.0570 0.0619 0.0525 0.0600 0.0600 24,872,714
Feb 19, 2024 0.0720 0.0730 0.0510 0.0600 0.0600 82,160,200
Feb 12, 2024 0.0890 0.0960 0.0770 0.0780 0.0780 78,923,400
Feb 05, 2024 0.0960 0.0960 0.0770 0.0840 0.0840 62,062,300
Jan 29, 2024 0.1090 0.1160 0.0930 0.0970 0.0970 92,774,500
Jan 22, 2024 0.1020 0.1480 0.0950 0.1130 0.1130 163,317,200
Jan 15, 2024 0.0980 0.1070 0.0860 0.1010 0.1010 42,693,800
Jan 08, 2024 0.1400 0.1400 0.1020 0.1030 0.1030 74,868,000
Jan 01, 2024 0.1520 0.1560 0.1310 0.1400 0.1400 15,049,600
Dec 25, 2023 0.1700 0.1750 0.1500 0.1510 0.1510 14,160,900
Dec 18, 2023 0.1650 0.1680 0.1460 0.1670 0.1670 19,167,400
Dec 11, 2023 0.2250 0.2290 0.1510 0.1600 0.1600 38,737,500
Dec 04, 2023 0.3500 0.4050 0.2650 0.2650 0.2650 28,157,100
Nov 27, 2023 0.3600 0.3830 0.2910 0.3560 0.3560 15,147,500
Nov 20, 2023 0.4250 0.5140 0.3300 0.3740 0.3740 30,015,800
Nov 13, 2023 0.2980 0.4210 0.2850 0.4070 0.4070 20,367,600
Nov 06, 2023 0.3000 0.3370 0.2580 0.2920 0.2920 19,674,600
Oct 29, 2023 0.3310 0.3640 0.3170 0.3200 0.3200 13,055,100
Oct 22, 2023 0.3220 0.4000 0.3000 0.3250 0.3250 16,088,700
Oct 15, 2023 0.3200 0.3750 0.2100 0.3300 0.3300 45,452,000
Oct 08, 2023 0.2520 0.5290 0.2250 0.3200 0.3200 142,429,30

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.